References

  1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-7. PubMed | Google Scholar

  2. Pignon JM. Translocation bcr-abl : méthodes diagnostiques et interêt clinique. Annale de Biologie clinique. 2001; 56(1) : 57-9. PubMed | Google Scholar

  3. Irenee Messanh Kueviakoe, Essohana Padaro, Kossi Agbetiafa, Yao Layibo, Malewè Kolou, Ahoefa Vovor, Akuete Segbena. Hematological Malignancies: analysis of myelogram results over 21 years in Lome Teaching Hospitals. Clinical Medicine Research. 2015; Vol4 (4): 111-115.

  4. Diop S, Ndoura A, Toure Fall AO, Thiam D, Diakhate L. Bone Marrow aspiration in diagnosis of hemopathies in Dakar, Senegal. Dakar Med. 2004; 49(2): 106-9. PubMed | Google Scholar

  5. Mukiibi JM, Nyirenda CM, Paul B et al. “Chronic myeloid leukaemia in central Africans”. East Afr Med J. 2003; 80 (9): 470 -5. PubMed | Google Scholar

  6. Dokekias AE, Malanda F, Mbalawa CH. Chronic myeloid leukaemia: what's the future therapy in Black Africa? Tunis Med. 2003; 81(3): 172-9. PubMed

  7. De Souza C, Vigorito A. Validation of the EBMT risk score in chronic myeloid in leukaemia in Brazil and allogeneic transplant. Haematologica. 2005; 90 (2): 932 -7. PubMed | Google Scholar

  8. Tardieu S, Brun- Strang C, Berthaud P et al. “Management of chronic myeloid leukelmia in France: a multicentered cross-sectional study on 538 patients”. Pharmacoepidemiol Drug Saf. 2005; 14 (8): 545-53. PubMed | Google Scholar

  9. Sureda A, Carrasco M.“Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukaemia. Haematologica”. 2003; 88 (11): 1213-20. PubMed | Google Scholar

  10. Tolo Diebkilé A, Koffi KG, Sawadogo GD et al. Impact thérapeutique de l'interféron alpha dans la prise en charge des patients de leucémie myéloïde chronique. Mali Med. 2010 ; tome XXV (n°1) : 22-27. PubMed

  11. Inokuchi K, Futaki M, Dan K, Nomura T. Possible correlation of b3-a2-type bcr-abl messenger RNA defined by semiquantitative RT-PCR to platelet and megakaryocyte counts in Philadelphia-positive chronic myelogenous leukemia. Intern Med. 1994 Apr; 33(4):189-92. PubMed | Google Scholar

  12. Inokuchi K, Inoue T, Tojo A, Futaki M, Miyake K, Yamada T, Tanabe Y, Ohki I, Dan K, Ozawa K et al. A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood. 1991 Dec 15;78(12):3125-7. PubMed | Google Scholar

  13. Ouédraogo SM, Hien F, Millogo A et al. Place des hémopathies malignes en service de médecine interne du CHU SOURO SANOU (Burkina-Faso).Mali Med. 2011;Tome XXVI( n° 3) : 17. PubMed

  14. Tanzer, Guilhot F. Leucémie myéloïde chronique en hématologie par BERNARD DREYFUS. Ed Flammarion. 1999; 620-642. In press

  15. Teillet F, Thiebaud, Dubreuil M. Etude de la leucémie myéloïde chronique. Encyclo Med Chir. 1986; Paris (France); Sang 13011 B20; 10. In press

  16. Brousted A. La leucémie myéloïde chronique in NAJMAN. Ed Ellipse; précis des maladies du sang. 1994; tome II Paris:24-41. PubMed

  17. Martiat P, Ifrah N, Rassol F, Morgan G, Giles F, Gow J, Goldman JM. Molecular analysis of Philadelphia positive essential thrombocythemia. Leukemia. 1989; 41(3):363-367. PubMed | Google Scholar